Non-invasive diagnosis of liver fibrosis and cirrhosis

World Journal of Gastroenterology

Volumn 21, Issue 41, 2015, Pages 11567-11583

  Lurie, Yoav ^a   Webb, Muriel ^b   Cytter Kuint, Ruth ^c   Shteingart, Shimon ^a   Lederkremer, Gerardo Z ^d  

^a HEBREW UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cirrhosis; Computerized tomography; Fibrosis; Liver; Magnetic resonance imaging; Non invasive; Serum biomarkers; Ultrasonography

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; ALPHA FETOPROTEIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GELATINASE A; HAPTOGLOBIN; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; BIOLOGICAL MARKER;

ACOUSTIC RADIATION FORCE IMPULSE IMAGING; ALANINE AMINOTRANSFERASE TO ASPARTATE AMINOTRANSFERASE RATIO; ARTICLE; ASPARTATE AMINOTRANSFERASE PLATELET RATION INDEX; BLOOD CELL RATIO; BODY MASS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; ECHOGRAPHY; ELASTOGRAPHY; FATTY LIVER; FOLLOW UP; GOLD STANDARD; HEPATITIS B; HEPATOBILIARY PARAMETERS; HUMAN; LIVER BIOPSY; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER FUNCTION TEST KIT; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERFUSION WEIGHTED IMAGING; STELLATE CELL; SUSCEPTIBILITY WEIGHTED IMAGING; THROMBOCYTE COUNT; BIOPSY; BLOOD; DIAGNOSTIC IMAGING; LIVER; METABOLISM; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; SEVERITY OF ILLNESS INDEX; X-RAY COMPUTED TOMOGRAPHY;

BIOMARKERS; BIOPSY; DIAGNOSTIC IMAGING; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84947249266     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i41.11567     Document Type: Article

References (160)

1. Major RH. Classic Descriptions of Disease. 3rd ed. Taiwan: Charles C Thomas Pub Ltd, 1978
2. Sherlock S. Diseases of the liver and biliary system. 3rd ed. Oxford: Blackwell Scientific publications, 1962
3. Bedossa P, Carrat F. Liver biopsy: the best, not the gold standard. J Hepatol 2009; 50: 1-3 [PMID: 19017551 DOI: 10.1016/j.jhep.2008.10.014]
4. Ch ild CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85 [PMID: 4950264]
5. Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Mezey E, White RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193-199 [PMID: 352788]
6. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218 [PMID: 15690074 DOI: 10.1172/jci24282]
7. Tsukada S,Parsons CJ,Rippe RA. Mechanisms of liver fibrosis Clin Chim Acta 2006 364 33-60 PMID: 16139830 DOI: 10.1016/j.cca.2005.06.014]
8. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001; 21: 311-335 [PMID: 11586463 DOI: 10.1055/s-2001-17550]
9. Gressner AM, Lotfi S, Gressner G, Haltner E, Kropf J. Synergism between hepatocytes and Kupffer cells in the activation of fat storing cells (perisinusoidal lipocytes). J Hepatol 1993; 19: 117-132 [PMID: 8301032]
10. Inagaki Y, Okazaki I. Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 2007; 56: 284-292 [PMID: 17303605 DOI: 10.1136/gut.2005.088690]
11. Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, Sarwar MT, Kausar H, Sumrin A, Shahid I, Hassan S. A brief review on molecular, genetic and imaging technique s for HCV fibrosis evaluation. Virol J 2011; 8: 53 [PMID: 21299910]
12. Liu T, Wang X, Karsdal MA, Leeming DJ, Genovese F. Molecular serum markers of liver fibrosis. Biomark Insights 2012; 7: 105-117 [PMID: 22872786 DOI: 10.4137/BMI.S10009]
13. Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango Gut 2010; 59: 861-866 [PMID: 20581229 DOI: 10.1136/gut.2010.214650]
14. Gressner OA, Gao C. Monitoring fibrogenic progression in the liver. Clin Chim Acta 2014; 433: 111-122 [PMID: 24607331 DOI: 10.1016/j.cca.2014.02.021]
15. De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. Clin Chim Acta 1957; 2: 70-74 [PMID: 13447217]
16. Giannini E, Botta F, Fasoli A, Ceppa P, Risso D, Lantieri PB, Celle G, Testa R. Progressive liver functional impairment is associated with an increa se in AST/ALT ratio. Dig Dis Sci 1999; 44: 1249-1253 [PMID: 10389705]
17. LA A. Non invasive diagnosis of fibrosis in NAFLD, how reliable is it? EASL postgraduate course metabolic liver disease. Vienna, Austria: The International Liver Congress, 2015: 24-25
18. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-Alcoholic fatty liver disease. Gut 2010; 59: 1265-1269 [PMID: 20801772 DOI: 10.1136/gut.2010.216077]
19. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526 [PMID: 12883497 DOI: 10.1053/jhep.2003.50346]
20. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan SY. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updat ed meta-Analysis. Hepatology 2011; 53: 726-736 [PMID: 21319189 DOI: 10.1002/hep.24105]
21. Zhu X, Wang LC, Chen EQ, Chen XB, Chen LY, Liu L, Lei XZ, Liu C, Tang H. Prospec tive evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB-4 in patients with chronic HBV infection. Dig Dis Sci 2011; 56: 2742-2749 [PMID: 21399926 DOI: 10.1007/s10620-011-1659-1]
22. Usluer G, Erben N, Aykin N, Dagli O, Aydogdu O, Barut S, Cevik F, Ormen B. Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C. Eur J Clin Microbiol Infect Dis 2012; 31: 1873-1878 [PMID: 22231498 DOI: 10.1007/s10096-011-1513-6]
23. Martin J, Khatri G, Gopal P, Singal AG. Accuracy of ultrasound and noninvasive markers of fibrosis to identify patients with cirrhosis. Dig Dis Sci 2015; 60: 1841-1847 [PMID: 25586089 DOI: 10.1007/s10620-015-3531-1]
24. Haseltine EL, Penney MS, George S, Ki effer TL. Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis. J Viral Hepat 2015; 22: 701-707 [PMID: 25582683 DOI: 10.1111/jvh.1 2382]
25. Halfon P, Carrat F, Bédossa P, Lambert J, Pénaranda G, Perronne C, Pol S, Cacoub P. Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patient s: the Fibrovic 2 Study-ANRS HC02. Antivir Ther 2009; 14: 211-219 [PMID: 19430096]
26. Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study. Eur J Gastro enterol Hepatol 2013; 25: 798-805 [PMID: 23395996 DOI: 10.1097/MEG.0b013e32835eb8bf]
27. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the predicti on of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46: 912-921 [PMID: 17705266 DOI: 10.1002/hep.21835]
28. WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection. Geneva: World Health Organization, 2014 [PMID: 25535634]
29. Reuben A. Leave gourmandising. Hepatology 2002; 36: 1303-1306 [PMID: 12395350]
30. Tapper EB, Krajewski K, Lai M, Challies T, Kane R, Afdhal N, Lau D. Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-Alcoholic fatty liver disease. Gastroenterol Rep (Oxf) 2014; 2: 276-280 [PMID: 25002154 DOI: 10.1093/gastro/gou034]
31. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a s ystemic review and meta-Analysis. Hepatology 2015; 61: 292-302 [PMID: 25132233 DOI: 10.1002/hep.27382]
32. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325 [PMID: 16729309 DOI: 10.1002/hep.21178]
33. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-36 [PMID: 17567829 DOI: 10.1002/hep.21669]
34. Stibbe KJ, Verveer C, Francke J, Hansen BE, Zondervan PE , Kuipers EJ, de Knegt RJ, van Vuuren AJ. Comparison of noninvasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scand J Gastroenterol 2011; 46: 962-972 [PMID: 21623677 DOI: 10.3109/00365521.2011.574725]
35. Amorim TG, Staub GJ, Lazzarotto C, Silva AP, Manes J, Ferronato Mda G, Shiozawa MB, Narciso-Schiavon JL, Dantas-Correa EB, Schiavon Lde L. Validation and comparison of simp le noninvasive models for the prediction of liver fibrosis in chronic hepatitis C. Ann Hepatol 2012; 11: 855-861 [PMID: 23109448]
36. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers R P, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Com p Hepatol 2004; 3: 8 [PMID: 15387887 DOI: 10.1186/1476-5926-3-8]
37. Poynard T, Ngo Y, Munteanu M, Thabut D, Ratziu V. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. Curr Hepat Rep 2011; 10: 87-97 [PMID: 21654911 DOI: 10.1007/s11901-011-0096-0]
38. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Metaanalyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40 [PMID: 17937811 DOI : 10.1186/1471-230x-7-40]
39. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V, Poyna rd T. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-Alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 6 [PMID: 16503961 DOI: 10.1186/1471-230x-6-6]
40. Poynard T, Moussalli J, Munteanu M, Thabut D, Lebray P, Rudler M, Ngo Y, Thibault V, Mkada H, Charlotte F, Bismut FI, Deckmyn O, Benhamou Y, Valantin MA, Ratziu V, Katlama C. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 2013; 59: 675-683 [PMID: 23712051 DOI: 10.1016/j.jhep.2013.05.015]
41. Forns X, Ampurdanés S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-992 [PMID: 12297848 DOI: 10.1053/jhep.2002.36128]
42. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013; 158: 807-820 [PMID: 23732714 DOI: 10.732 6 /0003-4819-158-11-201306040-00005]
43. McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relat ionship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000; 15: 945-951 [PMID: 11022838]
44. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-1873 [PMID: 16055434 DOI: 10.1373/clinchem.2005.048389]
45. Calés P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, KonatéA, Gallois Y, Ternisien C, Chevailler A, Lunel F. A novel panel of blood markers to assess the de gree of liver fibrosis. Hepatology 2005; 42: 1373-1381 [PMID: 16317693 DOI: 10.1002/hep.20935]
46. Boursier J, Brochard C, Bertrais S, Michalak S, Gallois Y, Fouchard-Hubert I, Oberti F, Rousselet MC, Calés P. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C. Aliment Pharmacol Ther 2014; 40: 178-188 [PMID: 24889599 DOI: 10.1111/apt.12813]
47. Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, Ferrari A, Alberti A. Stepwise combination algorithms of noninvasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006; 44: 686-693 [PMID: 16490278 DOI: 10.1016/j.jhep.2006.01.007]
48. Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H. Hepatology 2015: A clinical textbook. 6th ed. Germany: Flying publisher, 2015: 655
49. Gelse K, Pöschl E, Aigner T. Collagens-structure, function, and biosynthesis. Adv Drug Deliv Rev 2003; 55: 1531-1546 [PMID: 14623400]
50. Nøjgaard C,Johansen JS,Christensen E,Skovgaard LT,Price PA,Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease J Hepatol 2003 39 179-186 PMID: 12873813]
51. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ. Serum markers detect the pr esence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-1713 [PMID: 15578508]
52. Teare JP, Sherman D, Greenfield SM, Simpson J, Bray G, Catterall AP, Murray-Lyon IM , Peters TJ, Williams R, Thompson RP. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993; 342: 895-898 [PMID: 8105167]
53. Valva P, Casciato P, Diaz Carrasco JM, Gadano A, Galdame O, Galoppo MC, Mullen E, De Matteo E, Preciado MV. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chr onic infection. PLoS One 2011; 6: e23218 [PMID: 21858035 DOI: 10.1371/journal.pone.0023218]
54. Guéchot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluron an and type III procollagen aminoterminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996; 42: 558-563 [PMID: 8605673]
55. Montal to G, Soresi M, Aragona F, Tripi S, Carroccio A, Anastasi G, Magliarisi C, Barresi E, Notarbartolo A. [Procollagen III and laminin in chronic viral hepatopathies]. Presse Med 1996; 25: 59-62 [PMID: 8745719]
56. Schytte S, Hansen M, M øller S, Junker P, Henriksen JH, Hillingsø J, Teisner B. Hepatic and renal extraction of circulating type I procollagen aminopropeptide in patients with normal liver function and in patients with alcoholic cirrhosis. Scand J Clin Lab Invest 1999; 59: 627-633 [PMID: 10691054]
57. Maruyama K, Okazaki I, Takagi T, Ishii H. Formation and degradation of basement membrane collagen. Alcohol Alcohol Suppl 1991; 1: 369-374 [PMID: 1845565]
58. Tran A, Benzaken S, Saint-Paul MC, Guzman-Granier E, Hastier P, Pradier C, Barjoan EM, Demuth N, Longo F, Rampal P. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver di sease. Eur J Gastroenterol Hepatol 2000; 12: 989-993 [PMID: 11007134]
59. Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, Sugimoto K, Murata K, Nakano T. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCVassociated liver disease. World J Gastroenterol 2005; 11: 476-481 [PMID: 15641129]
60. Mylin AK, Rasmussen T, Johansen JS, Knudsen LM, Nørgaard PH, Lenhoff S, Dahl IM, Johnsen HE. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant pla sma cells. Eur J Haematol 2006; 77: 416-424 [PMID: 16930142 DOI: 10.1111/j.0902-4441.2006.t01-1-EJH2879.x]
61. Li F, Zhu CL, Zhang H, Huang H, Wei Q, Zhu X, Cheng XY. R ole of hyaluronic acid and laminin as serum markers for predicting significant fibrosis in patients with chronic hepatitis B. Braz J Infect Dis 2012; 16: 9-14 [PMID: 22358349]
62. Kanzler S, Baumann M, Schirmacher P, Dries V, Bayer E, Gerken G, Dienes HP, Lohse AW. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 2001; 8 : 430-437 [PMID: 11703574]
63. McClain C, Barve S, Joshi-Barve S, Song Z, Deaciuc I, Chen T, Hill D. Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfun ction in alcoholic liver disease. Alcohol Clin Exp Res 2005; 29: 180S-188S [PMID: 16344606]
64. Akpolat N, Yahsi S, Godekmerdan A, Demirbag K, Yalniz M. Relationship between serum cytokine level s and histopathological changes of liver in patients with hepatitis B. World J Gastroenterol 2005; 11: 3260-3263 [PMID: 15929178]
65. Zhang BB, Cai WM, Weng HL, Hu ZR, Lu J, Zheng M, L iu RH. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis. World J Gastroenterol 2003; 9: 2490-2496 [PMID: 14606082]
66. Gressner OA, Gressner AM. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int 2008; 28: 1065-1079 [PMID: 18783549 DOI: 10.1111/j.1478-3231.2008.01826.x]
67. Gressner OA, Lahme B, Demirci I , Gressner AM, Weiskirchen R. Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol 2007; 47: 699-710 [PMID: 17629588 DOI: 10.1016/j.jhep.2007.05.015]
68. Gressner AM, Yagmur E, Lahme B, Gressner O, Stanzel S. Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. Clin Chem 2006; 52: 1815-1817 [PMID: 16858074 DOI: 10.1373/clinchem.2006.070466]
69. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, Morel F, Zarski JP. Circulating mat rix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004; 99: 271-279 [PMID: 15046217]
70. Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002; 316: 71-81 [PMID: 11750276]
71. Walsh KM,Timms P,Campbell S,MacSween RN,Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and-2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis Dig Dis Sci 1999 44 624-630 PMID: 10080160]
72. Lavallard VJ, Bonnafous S, Patouraux S, Saint-Paul MC, Rousseau D, Anty R, Le Marchand-Bru stel Y, Tran A, Gual P. Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease. PLoS One 2011; 6: e17599 [PMID: 21445263 DOI: 10.1371/journal. pone .0017599]
73. Liu X, Wan X, Li Z, Lin C, Zhan Y, Lu X. Golgi protein 73(GP73), a useful serum marker in liver diseases. Clin Chem Lab Med 2011; 49: 1311-1316 [PMID: 21663469 DOI: 10.1515/CCLM.2011.640]
74. Morota K, Nakagawa M, Sekiya R, Hemken PM, Sokoll LJ, Elliott D, Chan DW, Dowell BL. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, ?-fetopro tein, and PIVKAII in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clin Chem Lab Med 2011; 49: 711-718 [PMID: 21231906 DOI: 10.1515/CCLM.2011.097]
75. Somme reyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFNlambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4: e1000017 [PMID: 18369468 DOI: 10.1371/journal.pp at.1000017]
76. Aoki Y, Sugiyama M, Murata K, Yoshio S, Kurosaki M, Hashimoto S, Yatsuhashi H, Nomura H, Kang JH, Takeda T, Naito S, Kimura T, Yamagiwa Y, Korenaga M, Imamura M, Masaki N, Izumi N, Kage M, Mizokami M, Kanto T. Association of serum IFN-?3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. J Gastroenterol 2015; 50: 894-902 [PMID: 25501286 DOI: 10.1007/s00535-014-1023-2]
77. Mölleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, Warscheid B, Broelsch C, Reiser M, Friedman SL, Tornøe I, Schlosser A, Klöppel G, Schmiegel W, Meyer HE, Holmskov U, Stühler K. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology 2009; 49: 1257-1266 [PMID: 19177598 DOI: 10.1002/hep.227 64]
78. Cheung KJ, Tilleman K, Deforce D, Colle I, Moreno C, Gustot T, Van Vlierberghe H. Usefulness of a novel serum proteome-derived index FI-PRO (fibrosis-protein) in the prediction of fibrosis in chroni c hepatitis C. Eur J Gastroenterol Hepatol 2011; 23: 701-710 [PMID: 21623191 DOI: 10.1097/MEG.0b013e3283471b74]
79. Ho AS, Cheng CC, Lee SC, Liu ML, Lee JY, Wang WM, Wang CC. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J Biomed Sci 2010; 17: 58 [PMID: 20630109 DOI: 10.1186/1423-0127-17-58]
80. Ito K, Kuno A, Ikehara Y, Sugiyama M, Saito H, Aoki Y, Matsui T, Imamura M, Korenaga M, Murata K, Masaki N, Tanaka Y, Hige S, Izumi N, Kurosaki M, Nishiguchi S, Sakamoto M, Kage M, Narimatsu H, Mizokami M. LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology 2012; 56: 1448-1456 [PMID: 22535703 DOI: 10.1002/hep.25815 ]
81. Qu Y, Gao CF, Zhou K, Zhao YP, Xu MY, Lu LG. Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B. Ann Hepatol 2012; 11: 202-212 [PMI D: 22345337]
82. Cho HJ, Kim SS, Ahn SJ, Park JH, Kim DJ, Kim YB, Cho SW, Cheong JY. Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B. Clin Mol Hepatol 2014 ; 20: 347-354 [PMID: 25548740 DOI: 10.3350/cmh.2014.20.4.347]
83. Gangadharan B, Antrobus R, Chittenden D, Rossa J, Bapat M, Klenerman P, Barnes E, Dwek RA, Zitzmann N. New approaches for biomarker discovery: the search for liver fibrosis markers in hepatitis C patients. J Proteome Res 2011; 10: 2643-2650 [PMID: 21410221 DOI: 10.1021/pr101077c]
84. Du S, Mao Y, Tong J, Li F, Che L, Li S, Yang H, Ba J, Hu N, Xing H, Lu X, Sang X, Zhang X, Wang X, Zhong S. A novel liver function evaluation system using radiopharmacokinetic modeling of technetium-99m-DTPA-galactosyl human serum albumin. Nucl Med Commun 2013; 34: 893-899 [PMID: 23744410 DOI: 10.1097/MNM.0b013e328362e7c7]
85. Pimstone NR, Stadalnik RC, Vera DR, Hutak D P, Trudeau WL. Evaluation of hepatocellular function by way of receptor-mediated uptake of a technetium-99m-labeled asialoglycoprotein analog. Hepatology 1994; 20: 917-923 [PMID: 7927233]
86. Benyair R, Kondratyev M, Veselkin E, Tolchinsky S, Shenkman M, Lurie Y, Lederkremer GZ. Constant serum levels of secreted asialoglycoprotein receptor sH2a and decrease with cirrhosis. World J Gastroenterol 2011; 17: 5305-5309 [PMID: 22219600 DOI: 10.3748/wjg.v17.i48.5305]
87. Veselkin E, Kondratyev M, Lurie Y, Ron E, Santo M, Reif S, Elashvili I, Bar L, Lederkremer GZ. A secreted form of the asialoglyc oprotein receptor, sH2a, as a novel potential noninvasive marker for liver fibrosis. PLoS One 2011; 6: e27210 [PMID: 22096539 DOI: 10.1371/journal.pone.0027210]
88. Hussain SM, Reinhold C, Mitchell DG. Cirrhosis and lesion characterization at MR imaging. Radiographics 2009; 29: 1637-1652 [PMID: 19959512 DOI: 10.1148/rg.296095508]
89. Faria SC, Ganesan K, Mwangi I, Shiehmorteza M, Viamonte B, Mazhar S, Peterson M, Kono Y, Santillan C, Casola G, Sirlin CB. MR imaging of liver fibrosis: current state of the art. Radiographics 2009; 29: 1615-1635 [PMID: 19959511 DOI: 10.1148/rg.296095512]
90. Huwart L, Sempoux C, Vicaut E, Salameh N, Annet L, Danse E, Peeters F, ter Beek LC, Rahier J, Sinkus R, Horsmans Y, Van Beers BE. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008; 135: 32-40 [PMID: 18471441 DOI: 10.1053/j.gastro.2008.03.076]
91. Singh S, Venkatesh SK, Wang Z, Miller FH, Motosugi U, Low RN, Hassanein T, Asbach P, Godfrey EM, Yin M, Chen J, Keaveny AP, Bridges M, Bohte A, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-Analysis of individual participant data. Clin Gastroenterol Hepatol 2015; 13: 440-451.e6 [PMID: 25305349 DOI: 10.1016/j.cgh.2014.09.046]
92. Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, Valasek M, Lin G, Brenner D, Gamst A, Ehman R, Sirlin C. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective stud y. Hepatology 2014; 60: 1920-1928 [PMID: 25103310 DOI: 10.1002/hep.27362]
93. Venkatesh SK, Wang G, Lim SG, Wee A. Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. Eur Radiol 2014; 24: 70-78 [PMID: 23928932 DOI: 10.1007/s00330-013-2978-8]
94. Venkatesh SK, Yin M, Takahashi N, Glockner JF, Talwalkar JA, Ehman RL. Non-invasive detection of liver fibrosis: MR imaging features vs. MR elastography. Abdom Imaging 2015; 40: 766-775 [PMID: 25805619 DOI: 10.1007/s00261-015-0347-6]
95. Wang Y, Ganger DR, Levitsky J, Sternick LA, McCarthy RJ, Chen ZE, Fasanati CW, Bolster B, Shah S, Zuehlsdorff S, Omary RA, Ehman RL, Miller FH. Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and dif fusion-weighted imaging. AJR Am J Roentgenol 2011; 196: 553-561 [PMID: 21343496 DOI: 10.2214/AJR.10.4580]
96. Godfrey EM, Patterson AJ, Priest AN, Davies SE, Joubert I, Krishnan AS, Gri ffin N, Shaw AS, Alexander GJ, Allison ME, Griffiths WJ, Gimson AE, Lomas DJ. A comparison of MR elastography and 31P MR spectroscopy with histological staging of liver fibrosis. Eur Radiol 2012; 22: 2790-2797 [PMID: 22752441 DOI: 10.1007/s00330-012-2527-x]
97. Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, Fidler JL, Ehman RL. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007; 5: 1207-1213.e2 [PMID: 17916548]
98. Batheja M, Vargas H, Silva AM, Walker F, Chang YH, De Petris G, Silva AC. Magnetic resonance elastography (MRE) in assessing hepatic fibrosis: performance in a cohort of patients with histological data. Abdom Imaging 2015; 40: 760-765 [PMID: 25542217 DOI: 10.1007/s00261-014-0321-8]
99. Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53: 325-335 [PMID: 21254180 DOI: 10.1002/hep.24013]
100. Papastergiou V, Tsochatzis E, Burroughs AK. Non-invasive assessment of liver fibrosis. Ann Gastroenterol 2012; 25: 218-231 [PMID: 24714123]
101. Haimerl M, Verloh N, Zeman F, Fellner C, Müller-Wille R, Schreyer AG, Stroszczynski C, Wiggermann P. Assessment of clinical signs of liver cirrhosis using T1 mapping on Gd-EOB-DTPA-enhanced 3T MRI. PLoS One 2013; 8: e85658 [PMID: 24392025 DOI: 10.1371/journal.pone.0085658]
102. Allkemper T, Sagmeister F, Cicinnati V, Beckebaum S, Kooijman H, Kanthak C, Steh ling C, Heindel W. Evaluation of fibrotic liver disease with whole-liver T1? MR imaging: a feasibility study at 1.5 T. Radiology 2014; 271: 408-415 [PMID: 24475807 DOI: 10.1148/radiol.13130342]
103. Rauscher I, Eiber M, Ganter C, Martirosian P, Safi W, Umgelter A, Rummeny EJ, Holzapfel K. Evaluation of T1? as a potential MR biomarker for liver cirrhosis: comparison of healthy control subjects and patients with liver c irrhosis. Eur J Radiol 2014; 83: 900-904 [PMID: 24661616 DOI: 10.1016/j.ejrad.2014.02.017]
104. Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, Sarania N, Philips R, Co llier JD, Booth JC, Schneider JE, Wang LM, Delaney DW, Fleming KA, Robson MD, Barnes E, Neubauer S. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol 2014; 60: 69-77 [PMID: 24036007 DOI: 10.1016/j.jhep.2013.09.002]
105. Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB. MR contrast agents for liver imaging: what, when, how. Radiographics 2006; 26: 1621-1636 [PMID: 17102040]
106. Lucidarme O, Baleston F, Cadi M, Bellin MF, Charlotte F, Ratziu V, Grenier PA. Non-invasive detection of liver fibrosis: Is superparamagnetic iron oxide particle-enhanced MR imag ing a contributive technique Eur Radiol 2003; 13: 467-474 [PMID: 12594548 DOI: 10.1007/s00330-002-1667-9]
107. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibr osis: noninvasive diagnosis with double contrast materialenhanced MR imaging. Radiology 2006; 239: 425-437 [PMID: 16641352]
108. Hughes-Cassidy F, Chavez AD, Schlang A, Hassanein T, Gamst A, Wolfson T, Sirlin C. Superparamagnetic iron oxides and low molecular weight gadolinium chelates are synergistic for direct visualization of advanced liver fibrosis. J Magn Reson Imaging 2007; 26: 728-737 [PMID: 176854 18 DOI: 10.1002/jmri.21066]
109. Bahl G, Cruite I, Wolfson T, Gamst AC, Collins JM, Chavez AD, Barakat F, Hassanein T, Sirlin CB. Noninvasive classification of hepatic fibrosis based on texture para meters from double contrastenhanced magnetic resonance images. J Magn Reson Imaging 2012; 36: 1154-1161 [PMID: 22851409 DOI: 10.1002/jmri.23759]
110. Balassy C, Feier D, Peck-Radosavljevic M, Wrba F, Witoszynskyj S, Kiefer B, Reiter G, Dai Y, Ba-Ssalamah A. Susceptibility-weighted MR imaging in the grading of liver fibrosis: a feasibility study. Radiology 2014; 270: 149-158 [PMID: 23925270 DOI: 10 .1148/radiol.13122440]
111. Razek AA, Abdalla A, Omran E, Fathy A, Zalata K. Diagnosis and quantification of hepatic fibrosis in children with diffusion weighted MR imaging. Eur J Radiol 2011; 78: 129-134 [PMID: 19926420 DOI: 10.1016/j.ejrad.2009.10.012]
112. Lewin M, Poujol-Robert A, Boëlle PY, Wendum D, Lasnier E, Viallon M, Guéchot J, Hoeffel C, Arrivé L, Tubiana JM, Poupon R. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 2007; 46: 658-665 [PMID: 17663420 DOI: 10.1002/hep.21747]
113. 3 Hagiwara M, Rusinek H, Lee VS, Losada M, Bannan MA, Krinsky GA, Taouli B. Advanced liver fibrosis: diagnosis with 3D wholeliver perfusion MR imaging-initial experience. Radiology 2008; 246: 926-934 [PMID: 18195377 DOI: 10.1148/radiol.2463070077]
114. Chen BB,Hsu CY,Yu CW,Wei SY,Kao JH,Lee HS,Shih TT. Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation o f liver fibrosis in chronic hepatitis patients Eur Radiol 2012 22 171-180 PMID: 21879400 DOI: 10.1007/s00330-011-2249-5]
115. Noren B, Dahlqvist O, Lundberg P, Almer S, Kechagias S, Ekstedt M, Franzén L, Wirell S, Smedby O. Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance spectroscopy. Eur J Radiol 2008; 66: 313-320 [PMID: 17646074]
116. Sangwaiya MJ, Sherman DI, Lomas DJ, Shorvon PJ. Latest developments in the imaging of fibrotic liver disease. Acta Radiol 2014; 55: 802-813 [PMID: 24226293 DOI: 10.1177/0284185113510 159]
117. Ronot M, Asselah T, Paradis V, Michoux N, Dorvillius M, Baron G, Marcellin P, Van Beers BE, Vilgrain V. Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT. Radiology 2010; 256: 135-142 [PMID: 20574090 DOI: 10.1148/radiol.10091295]
118. Romero-Gó mez M, Gómez-González E, Madrazo A, Vera-Valencia M, Rodrigo L, Pérez-Alvarez R, Pérez-Ló pez R, Castellano-Megias VM, Nevado-Santos M, Alcón JC, SoláR, Pérez-Moreno JM, Navarro JM, Andrade RJ, Salmerón J, Fernández-López M, Aznar R, Diago M. Optical analy sis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. Hepatology 2008; 47: 810-816 [PMID: 18098299 DOI: 10.1002/hep.22112]
119. Heller MT, Tublin ME. The role of ultrasonography in the evaluation of diffuse liver disease. Radiol Clin North Am 2014; 52: 1163-1175 [PMID: 25444098 DOI: 10.1016/j.rcl.2014.07.013]
120. Saverymuttu SH, Jo seph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986; 292: 13-15 [PMID: 3080046]
121. Harbin WP, Robert NJ, Ferrucci JT. Diagnosis of cirrhosis based on regional changes in hepatic morphology: a radiological and pathological analysis. Radiology 1980; 135: 273-283 [PMID: 7367613 DOI: 10.1148/radiology.135.2.7367613]
122. Gaia ni S, Gramantieri L, Venturoli N, Piscaglia F, Siringo S, D' Errico A, Zironi G, Grigioni W, Bolondi L. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study compar ing ultrasonography and percutaneous liver biopsy. J Hepatol 1997; 27: 979-985 [PMID: 9453422]
123. Di Lelio A, Cestari C, Lomazzi A, Beretta L. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology 1989; 172: 389-392 [PMID: 2526349 DOI: 10.1148/radiology.172.2.2526349]
124. Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D. Severe liver fibrosis or cirrhosis: accuracy of US for detection-Analysis of 300 cases. Radiology 2003; 227: 89-94 [PMID: 12601199 DOI: 10.1148/radiol.2272020193]
125. Abbattista T, Ridolfi F, Ciabattoni E, Marini F, Bendia E, Brunelli E, Busilacchi P. Diagnosis of liver cirrhosis by transit-time analysis at contrast-enhanced ultrasonography. Radiol Med 2008; 113: 860-874 [PMID: 18587531 DOI: 10.1007/s11547-008-0292-3]
126. Staub F, Tournoux-Facon C, Roumy J, Chaigneau C, Morichaut-Beauchant M, Levillain P, Prevost C, AubéC, Lebigot J, Oberti F, Galtier JB, Laumonier H, Trillaud H, Bernard PH, Blanc JF, Sironneau S, Machet F, Drouillard J, de Ledinghen V, Couzigou P, Foucher P, Castéra L, Tranquard F, Bacq Y, d'Altéroche L, Ingrand P, Tasu JP. Liver fibrosis staging wi th contrast-enhanced ultrasonography: prospective multicenter study compared with METAVIR scoring. Eur Radiol 2009; 19: 1991-1997 [PMID: 19259683 DOI: 10.1007/s00330-009-1313-x]
127. Goyal N, Jain N, Rachapalli V, Cochlin DL, Robinson M. Noninvasive evaluation of liver cirrhosis using ultrasound. Clin Radiol 2009; 64: 1056-1066 [PMID: 19822238 DOI: 10.1016/j.crad.2009.05.010]
128. Li N , Ding H, Fan P, Lin X, Xu C, Wang W, Xu Z, Wang J. Intrahepatic transit time predicts liver fibrosis in patients with chronic hepatitis B: quantitative assessment with contrast-enhanced ultrasonography. Ultrasound Med Biol 2010; 36: 1066-1075 [PMID: 20620694 DOI: 10.1016/j.ultrasmedbio.2010.04.012]
129. Gennisson JL, Deffieux T, Fink M, Tanter M. Ultrasound elastography: principles and techniques. Diagn Interv Imaging 2013; 94: 487-495 [PMID: 23619292 DOI: 10.1016/j.diii.2013.01.022]
130. Bamber J, Cosgrove D, Dietrich CF, Fromageau J, Bojunga J, Calliada F, Cantisani V, Correas JM, D'Onofrio M, Drakonaki EE, Fink M, Friedrich-Rust M, Gilja OH, Havre RF, Je nssen C, Klauser AS, Ohlinger R, Saftoiu A, Schaefer F, Sporea I, Piscaglia F. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: Basic principles and technology. Ultraschall Med 2013; 34: 169-184 [PMID: 23558397 DOI: 10.1055/s-0033-1335205]
131. Dietrich CF, Cantisani V. Current status and perspectives of elastography. Eur J Radiol 2014; 83: 403-404 [PMID: 23540945 DOI: 10.1016/j.ejrad.2013.02.028]
132. Tatsumi C, Kudo M, Ueshima K, Kitai S, Takahashi S, Inoue T, Minami Y, Chung H, Maekawa K, Fujimoto K, Akiko T, Takes hi M. Noninvasive evaluation of hepatic fibrosis using serum fibrotic markers, transient elastography (FibroScan) and real-time tissue elastography. Intervirology 2008; 51 Suppl 1: 27-33 [PMID: 18544945 DOI: 10.1159/00012260 2]
133. Meng F, Zheng Y, Zhang Q, Mu X, Xu X, Zhang H, Ding L. Noninvasive evaluation of liver fibrosis using real-time tissue elastography and transient elastography (FibroScan). J Ultrasound Med 2015; 34: 403-410 [PMID: 25715361 DOI: 10.7863/ultra.34.3.403]
134. Colombo S, Buonocore M, Del Poggio A, Jamoletti C, Elia S, Mattiello M, Zabbialini D, Del Poggio P. Head-to-head com parison of transient elastography (TE), real-time tissue elastography (RTE), and acoustic radiation force impulse (ARFI) imaging in the diagnosis of liver fibrosis. J Gastroenterol 2012; 47: 461-469 [PMID: 22223175 DOI: 10.1007/s00535-011-0509-4]
135. Sandrin L,Fourquet B,Hasquenoph JM,Yon S,Fournier C,Mal F,Christidis C,Ziol M,Poulet B,Kazemi F,Beaugrand M,Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis Ultrasound Med Biol 2003 29 1705-1713 PMID: 14698338]
136. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-973 [PMID: 17255218]
137. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatiti s C. Gastroenterology 2005; 128: 343-350 [PMID: 15685546]
138. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, Marcellin P, Dhumeaux D, Tr inchet JC, Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54 [PMID: 15690481 DOI: 10.1002/hep.20506]
139. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-847 [PMID: 18334275 DOI: 10.1016/j.jhep.2008.02.008]
140. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-Analysis of diagnostic accuracy. J He patol 2011; 54: 650-659 [PMID: 21146892 DOI: 10.1016/j.jhep.2010.07.033]
141. Chon YE, Choi EH, Song KJ, Park JY, Kim do Y, Han KH, Chon CY, Ahn SH, Kim SU. Performance of transient ela stography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-Analysis. PLoS One 2012; 7: e44930 [PMID: 23049764 DOI: 10.1371/journal.pone.0044930]
142. Sporea I, Sirli R, Deleanu A, Tudora A, Curescu M, Cornianu M, Lazar D. Comparison of the liver stiffness measurement by transient elastography with the liver biopsy. World J Gastroenterol 2008; 14: 6513-6517 [PMID: 19030204]
143. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-Analysis. Gastroenterology 2008; 1 34: 960-974 [PMID: 18395077 DOI: 10.1053/j.gastro.2008.01.034]
144. Cosgrove D, Piscaglia F, Bamber J, Bojunga J, Correas JM, Gilja OH, Klauser AS, Sporea I, Calliada F, Canti sani V, D'Onofrio M, Drakonaki EE, Fink M, Friedrich-Rust M, Fromageau J, Havre RF, Jenssen C, Ohlinger R, Sftoiu A, Schaefer F, Dietrich CF. EFSUMB guidelines and recommendations on the clinical use of ultrasound ela stography. Part 2: Clinical applications. Ultraschall Med 2013; 34: 238-253 [PMID: 23605169 DOI: 10.1055/s-0033-1335375]
145. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]
146. Shi KQ, Fan YC, Pan ZZ, Lin XF, Liu WY, Chen YP, Zheng MH. Transient elastography: a meta-Analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int 2013; 33: 62-71 [PMID: 22973991 DOI: 10.1111/liv.12003]
147. Calvaruso V, Bronte F, Conte E, Simone F, Craxí A, Di Marco V. Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepat itis C virus cirrhosis. J Viral Hepat 2013; 20: 867-874 [PMID: 24304456 DOI: 10.1111/jvh.12114]
148. Adebajo CO, Talwalkar JA, Poterucha JJ, Kim WR, Charlton MR. Ultrasound-based transien t elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-Analysis. Liver Transpl 2012; 18: 323-331 [PMID: 22140010 DOI: 10.1002/lt .22460]
149. Poynard T, Munteanu M, Luckina E, Perazzo H, Ngo Y, Royer L, Fedchuk L, Sattonnet F, Pais R, Lebray P, Rudler M, Thabut D, Ratziu V. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard. J Hepatol 2013; 58: 928-935 [PMID: 23321316 DOI: 10.1016/j.jhep.2012.12.021]
150. Bavu E, Gennisson JL, Couade M, Bercoff J, Mallet V, Fink M, Badel A, Vallet-Pichard A, Nalpas B, Tanter M, Pol S. Noninvasive in vivo liver fibrosis evaluation using supersonic shear imaging: a clinical study on 1 13 hepatitis C virus patients. Ultrasound Med Biol 2011; 37: 1361-1373 [PMID: 21775051 DOI: 10.1016/j.ultrasmedbi o.2011.05.016]
151. Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology 2012; 56: 2125-2133 [PMID: 22767302 DOI: 10.1002/hep.25936]
152. Leung VY, Shen J, Wong VW, Abrigo J, Wong GL, Chim AM, Chu SH, Chan AW, Choi PC, Ahuja AT, Chan HL, Chu WC. Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers: comparison of shear-wave elastography and transient elastography with liver biopsy correlation. Radiology 2013; 269: 910-918 [PMID: 23912619 DOI: 10.1148/radiol.13130128]
153. Zheng J, Guo H, Zeng J, Huang Z, Zheng B, Ren J, Xu E, Li K, Zheng R. Two-dimensional shear-wave elastography and conventional US: the optimal evaluation of liver fibrosis and cirrhosis. Radiology 2015; 275: 290-300 [ PMID: 25575116 DOI: 10.1148/radiol.14140828]
154. Palmeri ML, Wang MH, Dahl JJ, Frinkley KD, Nightingale KR. Quantifying hepatic shear modulus in vivo using acoustic radiation force. Ultrasound Med Biol 2008; 34: 546-558 [PMID: 18222031 DOI: 10.1016/j.ultrasmedbio.2007.10.009]
155. Friedrich-Rust M, Nierhoff J, Lupsor M, Sporea I, Fierbinteanu-Braticevici C, Strobel D, Takahashi H, Yoneda M, Suda T, Zeuzem S, Herrmann E. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-Analysis. J Viral Hepat 2012; 19: e212-e219 [PMID: 22239521 DOI: 10.1111/j.1365-2893.2011.01537.x]
156. Friedrich-Rust M, Wunder K, Kriener S, Sotoudeh F, Richter S, Bojunga J, Herrmann E, Poynard T, Dietrich CF, Vermehren J, Zeuzem S, Sarrazin C. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009; 252: 595-604 [PMID: 19703889 DOI: 10.1148/radiol.2523 081928]
157. Sporea I, Sirli RL, Deleanu A, Popescu A, Focsa M, Danila M, Tudora A. Acoustic radiation force impulse elastography as compared to transient elastography and liver biopsy in patients with chro nic hepatopathies. Ultraschall Med 2011; 32 Suppl 1: S46-S52 [PMID: 20603783 DOI: 10.1055/s-0029-1245360]
158. Sporea I, Bota S, Peck-Radosavljevic M, Sirli R, Tanaka H, Iijima H, Badea R, Lupsor M, Fierbinteanu-Braticevici C, Petrisor A, Saito H, Ebinuma H, Friedrich-Rust M, Sarrazin C, Ta kahashi H, Ono N, Piscaglia F, Borghi A, D'Onofrio M, Gallotti A, Ferlitsch A, Popescu A, Danila M. Acoustic Radiation Force Impulse elastography for fibrosis evaluation in patients with chronic hepatitis C: an interna tional multicenter study. Eur J Radiol 2012; 81: 4112-4118 [PMID: 23000186 DOI: 10.1016/j.ejrad.2012.08.018]
159. Bota S, Herkner H, Sporea I, Salzl P, Sirli R, Neghina AM, P eck-Radosavljevic M. Meta-Analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int 2013; 33: 1138-1147 [PMID: 23859217 DOI: 10.1111/liv.12240]
160. Spore a I, Bota S, Jurchis A, Sirli R, Grdinaru-Tascu O, Popescu A, Ratiu I, Szilaski M. Acoustic radiation force impulse and supersonic shear imaging versus transient elastography for liver fibrosis assessment. Ultrasound Med Biol 2 013; 39: 1933-1941 [PMID: 23932281 DOI: 10.1016/j.ultrasmedbio.2013.05.003]